BIOMAT Database Logo BIOMAT Database Logo

[Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia]. 1992

H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Third Department of Internal Medicine, Kochi Medical School, Nankoku, Japan.

Intensive induction chemotherapy was applied to 25 patients with acute myelogenous leukemia by continuing drugs (daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone) until the achievement of severe bone marrow aplasia (leukemic cells less than 1,000/microliters). Complete remission (CR) was achieved in 18 (72%). Numbers of partial remission and an early death were 5 (20%) and 2 (8%), respectively. Although median nadirs of white blood cells (WBC) and platelet counts (Pl) (205/microliters and 8,200/microliters, respectively) were remarkably low, recovery of WBC (over 1,000/microliters) and Pl (over 50,000/microliters) were achieved in 23.8 and 24.5 days, after an initiation of the chemotherapy. Sepsis was a most frequently observed complication during induction stage and a duration of fever was 2-48 days (median 15). Median duration of CR was 22.9 months. Unexpectedly, 11 of 17 CR (except one with bone marrow transplanted) relapsed after 4.2-41.4 months (median; 9.4), but 6 (35.3%) still remain in first CR for 30.5-72.9 months (median; 51.4). A long-term survival might be obtained by intensifying induction chemotherapy in about one fourth of patients, but the intensification or application of non-cross resistant anti-leukemic agents in post-remission therapy may be required to avoid relapses even if induction is intensified.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults.
December 1975, Cancer,
H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia.
January 1990, Haematology and blood transfusion,
H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
December 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
January 1994, Cancer chemotherapy and pharmacology,
H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
[Quadruple combination chemotherapy of acute leukemia using daunomycin, cytosine arabinoside, 6-mercaptopurine riboside and prednisolone].
December 1972, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Induction therapy and intensive consolidation with daunorubicin, cytosine arabinoside, and 6-thioguanine in adult acute nonlymphoblastic leukemia.
January 1981, Cancer clinical trials,
H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Combination chemotherapy with daunorubicin, cytosine arabinoside and prednisolone (DAP) in acute nonlymphocytic leukemia.
July 1981, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Successful re-induction therapy for acute myelogenous leukemia with cytosine arabinoside and daunorubicin.
January 1979, Cancer treatment reports,
H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside.
November 1977, Cancer treatment reports,
H Taguchi, and I Kubonishi, and N Takehara, and Y Uemura, and Y Iwahara, and T Eguchi, and T Miyagi, and S Sugito, and H Muneishi, and Y Tanaka
Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.
November 1975, Cancer,
Copied contents to your clipboard!